S
troke prevention in patients with nonvalvular atrial fibrillation (NVAF) has been the focus of substantial clinical investigation related to the increasing frequency of this arrhythmia with the aging population, the well-documented relationship between increasing age and increased stroke, and the particularly major morbidity/mortality from cardioembolic stroke (1) (2) (3) (4) (5) . Traditional treatment strategies have relied on chronic anticoagulation, either with warfarin or the newer anticoagulant agents (6) (7) (8) (9) . Growing information regarding the central role of left atrial appendage (LAA) thrombus has led to mechanical approaches for stroke prevention in this setting.
A number of catheter-and surgical-based strategies have been studied (10) (11) (12) (13) (14) (15) (16) ; with the exception of one randomized clinical trial (17) , the majority of the information regarding these approaches has been gathered from smaller registries (12) (13) (14) (15) (16) . In the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) study, LAA occlusion was documented to be noninferior to warfarin for the primary efficacy endpoint of stroke, cardiovascular death, and systemic embolism (SE) (17, 18) . However, several concerns were raised by the U.S. Food and Drug Administration regarding patient selection criteria (e.g., inclusion of patients with CHADS 2 [congestive heart failure, hypertension, age >75 years, diabetes mellitus, and previous stroke/transient ischemic attack] scores of 1) and acute safety events, particularly in the early portion of the trial, and a second trial was recommended (19) . To further evaluate the safety and efficacy of this approach for stroke prevention and to address these concerns, we 
MATERIALS AND METHODS
The multicenter, randomized clinical trial PREVAIL (NCT01182441) assessed the safety and efficacy of LAA closure with the Watchman device (Boston Scientific, St. Paul, Minnesota) compared with warfarin in patients with NVAF (paroxysmal, persistent, or permanent) and a CHADS 2 score $2. In accordance with contemporary guidelines for stroke prevention in AF, patients could be enrolled with a CHADS 2 score of 1 if they also had any of the following higher-risk characteristics: female age $75 years, baseline ejection fraction $30% but <35%, age 65 to 74 years and either diabetes or coronary disease, and age $65 years with congestive heart failure. These inclusion criteria were meant to include a higher risk group than had been evaluated in PROTECT AF. Exclusion criteria included requirement for long-term anticoagulation therapy for reasons other than AF, contraindication to warfarin or aspirin, previous stroke/transient ischemic attack within 90 days of enrollment, symptomatic carotid disease, or a patent foramen ovale or atrial septal defect requiring treatment. Patients in whom clopidogrel therapy was indicated were also excluded to minimize the confounding variable of chronic thienopyridines, which potentially could influence the incidence of stroke, thromboembolism, or bleeding (20) .
There were 3 coprimary endpoints. The first was primary efficacy, a composite of hemorrhagic or ischemic stroke, SE, and cardiovascular/unexplained death. The second was late-ischemic efficacy, a composite of ischemic stroke or SE, excluding the first 7 days after randomization. This endpoint had the goal School of Medicine, New York, New York. This study was sponsored by Atritech/Boston Scientific. Dr. Holmes (along with the Mayo Clinic) have a financial interest in technology related to this research; that technology has been licensed to Atritech. Dr. Kar receives research grants from Boston Scientific; is a member of the advisory board for left atrial appendage closure; is the national principal Other endpoints included stroke (both ischemic and hemorrhagic) or SE that resulted in significant disability, death, or all-cause mortality.
RANDOMIZATION AND MASKING. The study, which included up to 50 investigational sites in the United States, enrolled up to 475 patients; 407 were enrolled through randomization, and the remaining patients were enrolled through the roll-in process. A minimum of 20% of randomized patients were enrolled in institutions that had not participated in previous Watchman studies, and a minimum of 25% of the randomized patients were to be treated by new operators.
After screening, patients meeting the inclusion/ exclusion criteria were randomly assigned (by computer-generated randomization) to the device intervention or the control group (2:1 ratio). Randomization was stratified according to clinical center and was performed by using a centralized system using block sizes of 6 (4 interventions and 2 controls). The centralized computer system was password protected and accessed by the principal investigator and study coordinator after the patient gave consent and met inclusion criteria. Participants and clinicians were not masked to treatment assignment.
PROCEDURES. The Watchman device was implanted as previously described (17) . It is a self-expanding, nickel titanium (nitinol)-framed structure ranging in posterior distributions for the 18-month event rates
and calculating the probability of noninferiority. All follow-up information from the post-182-day period was used in the final hazards analysis in the model, contributing to the calculation of the probability of 18-month events.
For the primary efficacy endpoint, the rate ratio of The risk ratio criterion was used to mirror and expand on the criterion for the first endpoint. However, as the second endpoint of late stroke/SE is rarer than the first composite endpoint, the risk difference was established as part of the criteria for the second endpoint to provide adequate power. Achievement of either of these 2 criteria would satisfy noninferiority.
The sample size was determined based on an adaptive interim analysis in which the predictive probabilities of success for the 2 endpoints were calculated; enrollment was to be stopped early if the predictive probability of success at an interim analysis exceeded 0.95. Enrollment continued to the full maximum planned sample size because this threshold was not achieved during enrollment. Per the adaptive design, follow-up continued for 6 months after completion of enrollment, at which time the final analysis occurred.
The early safety primary endpoint was specific to the device arm and was analyzed simultaneous to the final analysis of the first 2 endpoints described earlier.
This model was a beta-binomial model with an historical prior, based on data from the device subjects in PROTECT AF and CAP (Continued Access PROTECT AF Registry) studies. This method became the performance goal for comparison (19 it was attempted (252 of 265). There were 4 patients in whom an implant was not attempted, even though they had been randomized to the device arm group.
Reasons for the aborted attempts were that the patient did not stop anticoagulation before the procedure (n ¼ 1), pre-implant TEE revealed a new LAA thrombus (n ¼ 1), and LAA size and shape were not optimal for the device (n ¼ 2). All patients had a minimum follow-up of 6 months. For randomized subjects, the mean follow-up was 11. Tables 2 and 3) .
Kaplan-Meier estimates for freedom from the primary efficacy endpoint are presented in Figure 2 . One stroke or SE occurred with warfarin (0.71%/patientyear), despite a mean CHADS 2 score of 2.6.
LATE-ISCHEMIC PRIMARY EFFICACY ENDPOINT. The rate of stroke or SE >7 days after randomization ( Kaplan-Meier estimates for this endpoint are presented in Figure 3 .
EARLY SAFETY PRIMARY ENDPOINT. The primary safety endpoint was evaluated only in the device group. CrIs were calculated from a Bayesian model that used PROTECT AF and the CAP Registry as prior sources and calculation of first event per subject.
Success for this endpoint was defined as being achieved if the percentage of patients experiencing one of the events was statistically less than the performance goal, defined as 2.67% with an upper bound of the 1-sided 95% CrI less than the performance goal (Table 5) . There were only 6 events meeting this safety primary endpoint in the 269 patients with device implantation. Accordingly, 2.2% of subjects experienced an event, and the 1-sided 95% CrI upper bound was 2.652%; therefore, success for this endpoint was achieved.
COMPARISON WITH EARLIER STUDIES. An early procedural hazard was of particular concern in the initial experience with LAA occlusion (19) ; therefore, several pre-specified comparisons were performed to assess the evolution of safety events over the course of the studies of the Watchman device. A total of 1,298 patients were treated with the Watchman device in 3 studies (PROTECT AF, CAP, and PREVAIL).
As per the protocol design, PREVAIL and CAP patients were at higher risk ( Abbreviations as in Tables 2 and 3 .
Holmes Jr et al. Table 7 ). 
DISCUSSION
The PREVAIL trial adds information to the initial pivotal PROTECT AF trial by using a Bayesian noninferiority design approach (21) . The major findings of the trial were: 1) LAA occlusion with the Watchman device was not noninferior to warfarin for the primary efficacy composite endpoint of all-cause stroke, cardiovascular or unexplained death, and SE, although the event rates with warfarin were significantly lower than expected, affecting the ability of the study to establish noninferiority; 2) the Watchman device was noninferior to warfarin for the occurrence of late ischemic events, such as ischemic stroke or SE Time (Months) Event Free Probability occurring after the first 7 days following randomization to isolate the effect of early periprocedural events from a longer term mechanism of action; and 3) the Watchman procedure met the pre-specified success criterion for safety events, even with a large proportion of operators without previous experience implanting the device within a higher risk patient population (Central Illustration).
The relationship between AF and stroke has been the subject of exhaustive study. Stroke in this setting has been predominantly thromboembolic in nature, secondary to LAA thrombus. This pathophysiology led to the widespread application of anticoagulant therapy, initially with warfarin, which has been proven superior to aspirin for stroke prevention (22) . At 45 months, the primary safety endpoint was noninferior for the device group because of the continued increase in adverse safety events with warfarin, (7) (8) (9) . In these trials, stroke and SE rates in the warfarin control arms were 1.7, 1.6, and 2.2 per 100 patient-years, respectively. In contrast, in PREVAIL, ischemic stroke in the warfarin control group was 0.71 per 100 patient-years (Fig. 4) . This unexpected, overperforming control group reduced the ability to establish noninferiority given the statistical trial design. One partial explanation for this finding may be related to the time-in-therapeutic range, which was 68% for PREVAIL versus 64%, 62%, and 55%, respectively, for RE-LY (7), ARISTOTLE (8) patients with nonvalvular atrial fibrillation (paroxysmal, persistent, or permanent) with a CHADS 2 (congestive heart failure, hypertension, age >75 years, diabetes mellitus, and previous stroke/transient ischemic attack) score $2. PREVAIL enrolled 407 patients; 269 were randomized to the device group and 138 to the control group. After successful implantation, 92.2%, 98.3%, and 99.3% of patients were able to discontinue warfarin after 45 days, 6 months, and 12 months, respectively. The 18-month event rates of the first primary efficacy endpoint were similar and expectedly low in both the device (0.064) and control (0.063) groups, yielding a mean 18-month rate ratio of 1.07. INR ¼ international normalized ratio.
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